Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
05 Junio 2024 - 3:05PM
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage
oncology company developing targeted therapies for patients with
RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D.,
Ph.D., the company’s chief executive officer and chairman, will be
a featured speaker in a fireside chat at the Goldman Sachs 45th
Annual Global Healthcare Conference.
Details of the company’s participation are as
follows:
- Goldman Sachs
45th Annual Global Healthcare
Conference Conference Dates: June 10-13, 2024Fireside Chat
Time/Date: 2:40 p.m. ET on Wednesday, June 12, 2024Location: Loews
Miami Beach Hotel, Miami, FL
To access a live webcast of the fireside chat,
please visit the “Events & Presentations” page of Revolution
Medicines’ website at
https://ir.revmed.com/events-and-presentations. Additionally, a
replay of the webcast will be available on the “Events &
Presentations” page of the Revolution Medicines website for at
least 14 days following the conference.
About Revolution Medicines,
Inc.Revolution Medicines is a clinical-stage oncology
company developing novel targeted therapies for RAS-addicted
cancers. The company’s R&D pipeline comprises RAS(ON)
inhibitors designed to suppress diverse oncogenic variants of RAS
proteins, and RAS companion inhibitors for use in combination
treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a
RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON)
G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective
inhibitor, are currently in clinical development. Additional
development opportunities include its RAS(ON) mutant-selective
inhibitors RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in
addition to RAS companion inhibitors RMC-4630 (SHP2) and RMC-5552
(mTORC1/4EBP1).
Media & Investor Contact
Erin Graves
650-779-0136
egraves@revmed.com
Revolution Medicines (NASDAQ:RVMD)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Revolution Medicines (NASDAQ:RVMD)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024